Palvella Therapeutics (PVLA) Non-Current Deffered Revenue (2016 - 2023)

Palvella Therapeutics (PVLA) has 8 years of Non-Current Deffered Revenue data on file, last reported at $759000.0 in Q2 2023.

• On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $759000.0 in Q2 2023; TTM through Jun 2023 was $759000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $18.7 million, down 51.22% from the prior year.
• Non-Current Deffered Revenue for Q2 2023 stood at $759000.0, down from $11.7 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for PVLA reached as high as $59.7 million in Q1 2019 and fell as low as $759000.0 in Q2 2023.
• Historically, Non-Current Deffered Revenue has averaged $35.6 million across 5 years, with a median of $37.8 million in 2020.
• Across the five-year window, Non-Current Deffered Revenue jumped 30.59% in 2021 and plunged 61.95% in 2023, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $47.3 million in 2019, then slipped by 24.03% to $35.9 million in 2020, then rose by 6.97% to $38.4 million in 2021, then sank by 51.22% to $18.7 million in 2022, then tumbled by 95.95% to $759000.0 in 2023.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $759000.0 in Q2 2023, $11.7 million in Q1 2023, and $18.7 million in Q4 2022.